OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Landgren on the Utility of MRD as an End Point in Multiple Myeloma Trials

May 29th 2024

C. Ola Landgren, MD, PhD, discusses the utility of minimal residual disease as an end point in clinical trials for the treatment of multiple myeloma.

Dr Yap on the Investigation of Saruparib in Solid Tumors

May 28th 2024

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.

Dr Baljevic on the PERSEUS Trial in Untreated Multiple Myeloma

May 28th 2024

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

Dr Dorritie on the NCRI-FLAIR Trial of Ibrutinib Plus Venetoclax in Previously Untreated CLL

May 24th 2024

Kathleen A. Dorritie, MD, discusses the significance of results from the phase 3 NCRI-FLAIR study in previously untreated chronic lymphocytic leukemia.

Dr Porter on Understanding Gaps in CAR T-Cell Therapy for R/R CLL

May 24th 2024

David L. Porter, MD, discusses knowledge gaps regarding the optimal use of CAR T-cell therapy in relapsed/refractory chronic lymphocytic leukemia.

Dr Baljevic on Key Considerations for Treatment Selection in Newly Diagnosed Multiple Myeloma

May 23rd 2024

Muhamed Baljevic, MD, discusses the consideration of patient comorbidities and preferences during treatment selection in newly diagnosed myeloma.

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

May 23rd 2024

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Dr Kitko on the Utility of Obe-Cel in Pediatric Patients With B-ALL

May 23rd 2024

Carrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Maxwell on Real-World Germline Variant Rates in Prostate Cancer

May 23rd 2024

Kara N. Maxwell, MD, PhD, discusses key takeaways from a real-world investigation of germline mutation rates in patients with metastatic prostate cancer.

Dr Lim on Multidisciplinary Approaches to Pancreatic Cancer Management

May 23rd 2024

Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.

Dr Gajewski on the Role of the Gut Microbiome in Immunotherapy Response Regulation

May 22nd 2024

Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.

Dr Krogsgaard on Phosphorylated Neoantigen Targets for Anticancer Vaccine Development

May 22nd 2024

Michelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.

Dr Leslie on the Utility of Axi-cel in High-Risk LBCL

May 22nd 2024

Lori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.

Dr Shitara on the Background of the CheckMate 649 Trial in GEJ Adenocarcinoma

May 22nd 2024

Kohei Shitara, MD, discusses the background of the phase 3 CheckMate 649 study in advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma.

Dr Tiwari on the Current Treatment Paradigms for HER2-Positive and HER2-Low Breast Cancers

May 22nd 2024

Shruti Tiwari, MD, discusses how the treatment paradigms for HER2-positive and HER2-low breast cancer has evolved in recent years.

Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer

May 22nd 2024

Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.

Dr Neelapu on Addressing CAR T-Cell Resistance in Lymphoma

May 22nd 2024

Sattva S. Neelapu, MD, discusses mechanisms of resistance to CAR T-cell therapies in lymphoma and how these areas of need may be addressed.

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

May 20th 2024

Sundar Jagannath, MBBS, discusses the FDA’s ODAC Meeting on safety considerations with ide-cel in multiple myeloma.

Dr Maxwell on the Accessibility of Genetic Testing in Metastatic Prostate Cancer

May 20th 2024

Kara N. Maxwell, MD, PhD, discusses the accessibility of genetic testing in the community setting for patients with metastatic prostate cancer.

Dr Lim on the Treatment of Resectable and Borderline Resectable Pancreatic Cancer

May 20th 2024

Kian-Huat Lim, MD, PhD, discusses the current standard of care for patients with resectable or borderline resectable pancreatic cancer.